Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

Trial number:
NCT04560166
Trial phase:
2
Study type:
Immunotherapy, Targeted therapy, Chemotherapy
Overall status:
Recruiting

Study start date

November, 2021

Scientific title

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor in Combination With Irinotecan and Temozolomide in Patients With High-Risk Neuroblastoma With Primary Refractory Disease or in First Relapse. An International, Single-Arm, Multicenter Phase 2 Trial.

Summary

An International, Single-Arm, Multicenter Phase 2 Trial.

Neuroblastoma (NB)Documented high-risk disease Receipt of Standard of Care (SoC) frontline induction/consolidation therapy (including surgery, chemotherapy, ASCT, MIBG, radiotherapy, immunotherapy, or retinoids)

Active disease despite previous aggressive multi-drug chemotherapy, defined as one of the following:

verified first progression during multi-drug frontline treatment orverified first episode of relapse, defined as recurrence after response to frontline treatment, or verified first designation of refractory disease, defined as persistent metastatic disease (SD or minor response by INRC and MIBG curie score ≥3) detected at conclusion of at least 4 cycles of multi-drug induction chemotherapy on or according to a high-risk NB treatment protocol as defined above

The patients must have one of the following (locally assessed) obtained within 3 weeks prior to enrollment and at least 10 calendar days after end of any prior anti-cancer treatment:

Measurable tumor on CT/MRI scan that is MIBG-avid or demonstrates increased FDG uptake on PET scanMIBG (Metaiodobenzylguanidine) scan with positive uptake at a minimum of one site. This site must represent disease recurrence after completion of therapy, progressive disease on therapy, or refractory disease during induction Age ≥ 12 months at enrollment Written informed consent

Myelodysplastic syndrome or any malignancy other than NBAny systemic anti-cancer therapy within 3 weeks Autologous stem cell transplant (ASCT) within 6 weeks prior to enrollment or ongoing toxicity due to the stem cell transplant at the discretion of the investigator Therapeutic 131I-MIBG within 6 weeks prior to enrollment Radiotherapy (RT) within 4 weeks prior to enrollment at any lesion site that will be identified as a target lesion to measure tumor response Prior treatment with anti-GD2 if the patient experienced Progressive Disease (PD) while on anti-GD2 treatment Receipt of second line chemotherapy after designation of primary refractory disease or first relapse or PD NB in Bone Marrow (BM) only NB in the Central Nervous System (CNS) or leptomeningeal disease within 6 months prior to enrollment Performance status of < 50% as per the Lansky scale (patients less than 16 years of age) or Karnofsky scale (for patients aged 16 years or older) Life expectancy of less than 6 months Left ventricular ejection fraction < 50% by echocardiography Inadequate pulmonary function Diarrhea Grade ≥ 2 Treatment with long-acting myeloid growth factor within 14 days or short-acting myeloid growth factor within 7 days prior to first dose of GM-CSF Receipt of immunosuppressive treatment (local steroids excluded) within 4 weeks prior to enrollment Life threatening infection(s) Uncontrolled seizure disorders despite anticonvulsant therapy (defined as a seizure event within 3 months prior to enrollment) Treatment with enzyme-inducing anticonvulsants including phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to enrollment Concomitant use with St John's wort Allogeneic hematopoietic stem cell transplantation (allo-SCT) or donor-lymphocyte-infusion (defined as any kind of active allogeneic lymphocyte suspension) Treatment with Hematopoietic Progenitor Cell (HPC) boost within 2 months prior to enrollment History of allergy or known hypersensitivity to GM-CSF, yeast-derived products, or any component of GM-CSF, naxitamab, irinotecan or temozolomide History of anaphylactic reactions CTCAE Grade 4 related to prior anti-GD2 antibody therapy

Unacceptable hematological status at screening, defined as one of the following:

Hemoglobin <5.0 mmol/L (<8 g/dL)White blood cell count <1000/µL Absolute neutrophil count <750/µL Platelet count < 75,000/µL

Unacceptable liver function at screening, defined as one of the following:

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >5 times upper normal limit (UNL)Total bilirubin >1.5 x UNL Unacceptable kidney function at screening, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 calculated by the 2009 revised Bedside Schwartz Equation Inability to comply with protocol Significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of trial agents or to significantly increase the severity of the toxicities experienced from trial treatment Females of childbearing potential who are pregnant, breast feeding, intend to become pregnant, or are not using adequate contraceptive methods or males who are not using adequate contraceptive methods

Study design

Primary purpose: Treatment, Allocation: N/A, Intervention model: Single Group Assignment, Masking: None (Open Label),

Conditions

Neuroblastoma Recurrent

Other study ID numbers

203

Choose trial site (10)

Farrer Park
Farrer Park Active, not recruiting